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Background. B-type natriuretic peptide has been shown to be a very sensitive and speciﬁc marker of heart failure. In this study,
w ea i m e dt oi n v e s t i g a t et h ee ﬀect of percutaneous closure of ventricular septal defects with Amplatzer septal occluders on brain
natriuretic peptide levels. Methods. Between 2008 and 2011, 23 patients underwent successfully percutaneous ventricular septal
defect closure in 4 cardiology centers. Brain natriuretic peptide levels were measured in nine patients (4 male, mean ages were
25.3±14.3)whounderwentpercutaneousclosurewithAmplatzeroccludersformembranousormuscularventricularseptaldefects
were enrolled in the study. Brain natriuretic peptide levels were measured one day before and one month after the closure. Patients
were evaluated clinically and by echocardiography one month after the procedure. Results. Percutaneous closures of ventricular
septal defects were successfully performed in all patients. There was not any signiﬁcant adverse event in patients group during
followup. Decrease in brain natriuretic peptide levels after closure were statistically signiﬁcant (97.3 ± 78.6v e r s u s2 6 .8 ± 15.6,
P = 0.013). Conclusion. Brain Natriuretic Peptide levels are elevated in patients with ventricular septal defects as compared to
controls. Percutaneous closure of Ventricular Septal Defect with Amplatzer occluders decreases the BNP levels.
1.Introduction
Ventricular Septal Defect (VSD) is the most common con-
genital heart defect and seen in approximately 30% of all
congenital heart lesions [1–5]. Up to 70% of these VSDs
are localized in perimembranous region, and most of these
defects require invasive treatment due to the heart failure,
left heart volume overload, evolving aortic regurgitation, or
following endocarditis [1, 6–11]. Surgery is still standard
treatment, but this procedure is more invasive than percuta-
neous closure and requires cardiopulmonary bypass and car-
dioplegic arrest. Surgical treatment has negative impact on
quality of life of patients because of incisional trauma, lim-
itations on activity after surgery and surgical scars [1–14].
Therefore, percutaneous closure of VSD has become an imp-
ortant alternative option to surgical treatment. Nowadays,
most of the VSDs are increasingly being successfully closed
by percutaneous approach [1–11].
Brain natriuretic peptide (BNP) is a neurohormone
released by cardiac ventricles in response to volume and
pressure load [4, 5, 12, 13]. These natriuretic hormones have
important role on regulating extracellular ﬂuid volume and
blood pressure. BNP is a circulating mediator that has been
correlated with the degree of heart failure and higher in
patients with VSDs as a result of hyperkinetic circulation
[4, 5, 12, 13]. In this study, we evaluated the BNP levels one
day before and one month after the percutaneous closure of
VSDs with Amplatzer occluders in adults and children.2 The Scientiﬁc World Journal
Table 1: Patient characteristics and procedures.
Patient no. Age (yrs) Gender ECG Occluder type Defect size
(mm)
Occluder size
(mm)
Number of
device
BNP 1 BNP 2
18 F S R MUSC 10 12 1 94 35
23 4 F S R MEMB+ASD 3 4
ADO 2 1 66 12
32 2 F S R MUSC 5 6 1 84 26
42 1 F S R MUSC 6 8 1 77 30
51 9 M S R MEMB+ MUSC 8 10 2 65 16
65 3 M S R MUSC 6 8 1 303 60
73 8 M S R MUSC 5 6 1 45 36
82 4 F S R MUSC 8 10 1 86 15
99 M S R MUSC 5 6 1 56 12
2.MaterialsandMethods
Between 2008 and 2011, total of 23 patients underwent suc-
cessfully percutaneous VSD closure attempt in 4 cardiology
centers. BNP levels were measured in nine patients (4 male,
mean age was 25.3 ± 14.3) who underwent percutaneous
closure with Amplatzer occluders for membranous or
muscular Ventricular Septal Defects enrolled in the study.
BNP levels were measured day before and thirty days
after the closure. Patients were evaluated clinically and by
echocardiography one month after the procedure. Inclusion
criteria: clinical and/or echocardiographic evidence of a
signiﬁcant left-to-right shunt through the VSD if there were
one of those criteria: cardiomegaly on chest X-ray, left atrial
enlargement, deﬁned as left atrial to aortic ratio >1.5, left
ventricular enlargement (left ventricular volume overload),
deﬁned as a left ventricular end-diastolic diameter ≥2
standard deviations (SD) above the average for the patient’s
age, symptoms including frequent respiratory infections
and/or failure to thrive, and a New York Heart Association
functional class II or greater. Frequent respiratory infections
were deﬁned as more than six events a year. Failure to thrive
was deﬁned according to the literature [2]. We found that
patients who were ≥5y e a r so l da n d≥15kg would be eligible
for percutaneous closure of VSD. Only subjects with a rim of
at least 2mm separating the aortic valve from the VSD were
included. Patients who have operated before for VSD and
have signiﬁcant residual shunt from the repaired area were
also included. We excluded patients with VSD and prolapse
of an aortic cusp and patients with VSD and misalignment.
Patients with larger than 12mm VSD and pulmonary artery
pressure greater than 2/3 of systemic arterial pressure were
also excluded the study.
Patients or parents of the children gave their written
informed consent to the procedure. The patients’ general
characteristics are reported in Table 1.
Awrittenconsentwasobtainedfromallpatients,andour
local ethical committee approved the study.
2.1. Device, Procedure, and Delivery Systems. The muscu-
lar or membranous Amplatzer VSD occluder device and
Amplatzer duct occluder II device were (AGA Medical
Corporation, Golden Valley, MN, USA) used for closure
in all patients as was described previously [1–11, 15]. The
thickness of wire for the 12 and 14mm devices is 0.0059; the
rest of devices are made from 0.0049 Nitinol wire.
Right femoral vein and artery sheaths were placed. Right
and left cardiac catheterization was performed ﬁrstly. The
shunt volume was calculated by echocardiographic and
oximetric measurements [16]. Left ventriculography was
performed in LAO cranial and left lateral projections. VSD
defect size, distance to aortic and tricuspid valves, was
evaluated LAO cranial and left lateral projections. The device
whichwillbeusedforclosingwasdecidedusingangiography
and transthoracic echocardiography. The device was chosen
1-2mm larger than the size of the VSD.
Implantation of the VSD occluder was performed ac-
cording to standard techniques previously described under
the guidance of transthoracic and transesophageal echocar-
diography [1–11]. VSD was passed through by right Judkins’
catheter via aorta, and a hydrophilic 0.035inch wire was
placed to pulmonary artery. Catheter was pushed, and wire
was changed by noodle wire and it was captured by a snare in
the pulmonary artery and wire pulled back from the femoral
vein sheath. During the catheter was in VSD region, delivery
sheath was advanced over the noodle wire and the dilator
slowly drawn back, and the sheath was pushed toward the
apexoftheLV.Thedevicewasscrewedintothecable,leftside
of the device opened ﬁrst, and right side of the device was
openedaftercontrolleftventricularangiography.Iftheresult
wassatisfactory,thendevicewasreleasedandcontrolangiog-
raphy and echocardiography was performed and repeated
10 minute after device release (Figures 1(a), 1(b),a n d1(c)).
Hemostasis was achieved, and patients recovered overnight.
Heparin was used in all patients to keep the activated
clotting time greater than 200sec, and antibiotic prophylaxis
was given at the beginning of the case and two doses
thereafter. Next day, transthoracic echocardiography, chest
radiograph, and ECG were performed prior to discharge
from the hospital. All patients underwent complete cardiac
and laboratory evaluation after 1 month, at 6 months, and
after 1 year.
BNPlevelsweremeasuredonedaybeforeandonemonth
after the percutaneous closure of VSDs with AmplatzerThe Scientiﬁc World Journal 3
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Figure 1: (a) Muscular VSD before the closure, (b) muscular VSD during the occluder device positioned, (c) muscular VSD successfully
occluded by the device after closure.
occluders. One month later, all patients were evaluated clin-
ically and by echocardiography. Written informed consent
was obtained in all patients.
3.StatisticalAnalysis
Statistical analysis was performed using the Statistical Pack-
ageforSocialSciences(SPSS,Chicago,IL,USA),version15.0
software for Windows. Descriptive statistics were made, and
a l ld a t aw e r ee x p r e s s e da sm e a n±standard deviation and %
ratio. The quantitative values between pre- and postproce-
dures were compared using paired sample t-test. P value of
<0.05 was considered as statistically signiﬁcant in all cases.
4. Results
Tables 1,a n d2 summarize the patients’ clinical, demo-
graphic, and procedural data. Percutaneous closures of VSDs
were successfully performed in all patients. The median
age of the patients was 25.3 years (range 8–53 years). The
median size of VSD was 7.0mm (range 4–12) as measured
by transthoracic echocardiography.
There was not any death or urgent cardiac surgery
required complication. There was one device embolization
which was seen in patient number 3. The embolized device
was stuck in abdominal aorta, and snare retrieval was tried
before but yielded unsuccessful. Device was rescrewed and
replaced to the VSD defect region successfully.
Third-degree atrioventricular block was occurred in one
patient, and temporary pace maker was inserted for 24
hours. Normal sinusal rhythm was restored after 12 hours
monitoring, and 1mg/kg cortisone was administered for
this patient by intravenous route. Intradevice residual shunt
remained in 3 patients for 3 days and residual shunt was
remainedinonepatient.Mildgroinhematomawasoccurred
in three patients.
There was not death, endocarditis, or device-related
complication in the follow-up period. Residual shunt was
remained in one patient in whom the defect was closed by
ADO II and simultaneous ASD closure.4 The Scientiﬁc World Journal
Followup. Mean preprocedural BNP level obtained one day
before the closure was 97.3 ± 78.6pg/mL. BNP levels
measuredonemonthaftertheclosuredecreasedinallpatient
compared with the preprocedural values (26.8 ± 15.6). This
decrease was statistically signiﬁcant (P = 0.013), Table 2 and
Figure 2.
5. Discussion
VSDs with left ventricular volume overload require closure
in order to prevent ventricular dilatation and dysfunction,
arrhythmias, aortic regurgitation, pulmonary artery hyper-
tension, and endocarditis [1–18]. Percutaneous closure of
VSD is alternative method to surgery in selected cases. This
procedurehasless negative impacton patient’s quality of life;
the hospital stay is shorter and causes less pain to surgical
treatment. Recent studies in the literature showed that the
rate of successful closure has been between 90 and 100% [1–
11].
In our study, percutaneous closures of VSDs were
successfully performed in 23 patients, and none of the
patients need emergency cardiac surgical. The rate of major
complications reported in the literature ranges between 0
and 8.6% [1–17]. In our study group, device embolization
occurred only in one patient, and the embolized device was
rescrewed and removed form the abdominal aorta. VSD in
that patient was closed successfully with the same device.
Residual shunt was observed in 3 patients after closure.
Only in one, residual shunt remained during the followup
in whose the defect was closed by ADO II. The most signif-
icant early complication after percutaneous VSD closure is
atrioventricular block. The complete atrioventricular block
rates reported in the literature ranges between 0 and 5.7%
[1, 2, 5–13]. In our study complete atrioventricular block
was developed in one patient and temporary pacemaker
implanted. Block disappeared 24 hours later.
BNP is a neurohormone released by cardiac ventricles
in response to volume and pressure load. These natriuretic
hormones are thought to be a sensitive and speciﬁc indicator
of ventricular function [17, 19]. Recent studies have shown
that serum BNP level has increased during diﬀerent types
of hemodynamic overload of the heart including VSDs [17,
19]. BNP is correlated with the degree of heart failure and
higher in patients with VSDs as a result of hyperkinetic
circulation and volume overload. Suda et al. [17]r e p o r t e d
that plasma BNP levels signiﬁcantly positively correlated
withpulmonary-to-systemicﬂowratioandmeanpulmonary
artery pressure in children with VSD [4, 5, 12–16]. In our
study, we have evaluated the BNP levels one day before
and one month after the percutaneous closure. Values of
BNP were under the diagnostic limits for overt congestive
heart failure. It is possible to explain these BNP values by
the absence of overt congestive heart failure and patient’s
c h a r a c t e r i s t i c ss u c ha ss e l e c t e ds m a l lt om o d e r a t eV S D sw i t h
mild pulmonary artery pressure. We observed signiﬁcant
decrease in BNP levels in all patients compared with the
values before closure. These ﬁndings are thought to be
a result of the regression of hypervolemic situation and
slowdown of hyperkinetic circulation caused by VSD.
Table 2: Summary of procedure data.
Fluoroscopic time (min) 25 ±20 (range 15–112)
Procedure time (min) 90 ±51 (range 40–145)
Qp/Qs 1.6 ±0.76 (range 1.2–3.5)
Systolic PA pressure (mmHg) 48 ±9
Mean PA pressure (mmHg) 27 ±6
VSD diameter on TTE (mm) 7 ±2 (range 4–12)
Types of devices used
mVSD-O 1 patient
pmVSD-O 7 patients
ADO II 1 patient
Multiple devices 1 patient
BNP (pg/mL)
Before
closure
30 days
after closure P
97.3 ±78.62 6 .8 ±15.6 0.013
400
300
200
100
0
123456789
P = 0.013
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Figure 2: BNP levels before and after VSD closure.
In conclusion, BNP is relatively cheap, noninvasive,
rapid, and widely available cardiac biomarker. The current
study suggests that serum BNP level may provide a useful
clinical tool in evaluation of patients with VSD after
the closure. Decrease in serum BNP levels may indicate
hemodynamic improvement, so measurement of BNP level
may oﬀer an objective method in the clinical evaluation of
the patients who underwent percutaneous closure of VSD.
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